Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.

Por Erba, E., Sen, S., Sessa, C., Vikhanskaya, F. L., D'Incalci, M.
Publicado em 1994

Natural cytotoxicity on tumour cells of human macrophages obtained from diverse anatomical sites.

Por Mantovani, A, Bar Shavit, Z, Peri, G, Polentarutti, N, Bordignon, C, Sessa, C, Mangioni, C
Publicado em 1980

Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

Por Morasca, L., Erba, E., Vaghi, M., Ghelardoni, C., Mangioni, C., Sessa, C., Landoni, F., Garattini, S.
Publicado em 1983

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer

Por Ghielmini, M, Pagani, O, Jong, J de, Pampallona, S, Conti, A, Maestroni, G, Sessa, C, Cavalli, F
Publicado em 1999

Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins

Por Proebstle, T M, Alm, B J, Göckeritz, O, Wenzel, C, Noppeney, T, Lebard, C, Sessa, C, Creton, D, Pichot, O
Publicado no Br J Surg (2015)

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968)

Por Joerger, M, Hess, D, Delmonte, A, Gallerani, E, Fasolo, A, Gianni, L, Cresta, S, Barbieri, P, Pace, S, Sessa, C
Publicado no Br J Clin Pharmacol (2015)

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

Por Ghielmini, M., Bosshard, G., Capolongo, L., Geroni, M. C., Pesenti, E., Torri, V., D'Incalci, M., Cavalli, F., Sessa, C.
Publicado em 1997

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

Por Sulkes, A., Smyth, J., Sessa, C., Dirix, L. Y., Vermorken, J. B., Kaye, S., Wanders, J., Franklin, H., LeBail, N., Verweij, J.
Publicado em 1994

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies

Por Leyvraz, S, Herrmann, R, Guillou, L, Honegger, H P, Christinat, A, Fey, M F, Sessa, C, Wernli, M, Cerny, T, Dietrich, D, Pestalozzi, B
Publicado em 2006

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

Por Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L
Publicado em 2014

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

Por Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Publicado em 2013

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

Por Colombo, N, McMeekin, D S, Schwartz, P E, Sessa, C, Gehrig, P A, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, P F, Einstein, M H, Haluska, F
Publicado em 2013